Delivery of a healthy child 30 weeks after resuscitation for thromboembolism and treatment with danaparoid: 5-year follow up.
Weilbach
Christian
C
Rahe-Meyer
Niels
N
Raymondos
Kostas
K
Piepenbrock
Siegfried
S
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002657:Child Development / Q000187:drug effects*; D002675:Child, Preschool; D002809:Chondroitin Sulfates / Q000009:adverse effects / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D004280:Dobutamine / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005865:Gestational Age; D006497:Heparan Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009154:Mutation; D009638:Norepinephrine / Q000627:therapeutic use; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000235:genetics; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000235:genetics; D012121:Respiration, Artificial / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000925:Anticoagulants; D002316:Cardiotonic Agents; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004280:Dobutamine; D005165:Factor V; D006497:Heparan Sulfate; D009638:Norepinephrine; D014662:Vasoconstrictor Agents; C095381:factor V Leiden; C035838:danaparoid